<- Go Home
BiomX Inc.
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company’s product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Market Cap
$17.0M
Volume
88.9K
Cash and Equivalents
$23.5M
EBITDA
-$31.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$8.55
52 Week Low
$0.48
Dividend
N/A
Price / Book Value
0.88
Price / Earnings
-0.25
Price / Tangible Book Value
4.29
Enterprise Value
$21.9M
Enterprise Value / EBITDA
-0.78
Operating Income
-$32.3M
Return on Equity
37.81%
Return on Assets
-43.41
Cash and Short Term Investments
$23.5M
Debt
$9.7M
Equity
$37.9M
Revenue
N/A
Unlevered FCF
-$18.3M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium